Clinical Trial

Dexamethasone for Treating Severe Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype

Study acronym: HAP-DEX
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated August 11, 2025 (before its estimated March 14, 2026 completion). Its status may not reflect the trial's current state.
Summary
Determine the efficacy of dexamethasone plus standard of care (SOC) as compared to placebo plus SOC for treating severe hospital-acquired pneumonia in critically ill patients with a proinflammatory phenotype; It's an international phase III, double-blind, placebo-controlled, randomized trial.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-02-20; most recent amendment 2025-08-05.
Status change: Not Yet Recruiting → Recruiting 2024-12-03
Trial Details
NCT Number NCT06269900
Lead Sponsor Nantes University Hospital
Conditions Hospital Acquired Pneumonia
Enrollment 450 participants
Start Date 2024-03-26
Primary Completion 2026-03-14 (estimated)
Study Completion 2026-08-15 (estimated)
Updated on ClinicalTrials.gov 2025-08-11